FDA Needs More Aggressive Globalization Strategy – Sen. Brown
This article was originally published in The Tan Sheet
Executive Summary
The Ohio Democrat says FDA should be more creative in dealing with globalization problems than asking for funds to put more inspectors in China. Commissioner Hamburg says the agency is aggressive but lacks tools and resources to fully address globalization issues.
You may also be interested in...
FDA Toots Its Own Horn On Safety Of Marketed Drugs, Imports
FDA’s Global Engagement report describes the agency’s actions to protect the international supply chain. Meanwhile, the Advances in FDA’s Safety Program for Marketed Drugs report notes label changes and safety studies mandated under its post-market drug safety program.
Foreign Regulatory Systems Can Be Strengthened By Receiving FDA Inspection Data, IOM Says
Institute of Medicine report recommends how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad. It calls for FDA to provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.
FDA Highlights Hands-On Approach To China Inspections In Budget Plan
The budget request targets an increase in pharmaceutical programs’ budget authority to boost the number of FDA staff focused on China’s manufacturing. The proposed $10 million increase, including $5.6 million to be allocated toward manufacturing, provides for additional inspections, educational efforts and inspectors in China.